News

Iconovo and TOA sign agreement for development of a generic product

November 19, 2021

Iconovo AB (publ), that develops complete inhalation products for a global market, and TOA Pharmaceutical Co., Ltd, which develops generic…

First granted ICOone® patent in China

November 1, 2021

The Chinese Patent Office has announced the intention to grant a patent (Notice of Allowance) regarding Iconovo’s inhalation device ICOone. Iconovo…

Iconovo Q3-2021 quarterly report

October 29, 2021

New nasal inhaler has great potential in treatment of COVID-19 Key figures in TSEK unless otherwise indicated Jul-Sep 2021 Jul-Sep 2020 Jan-Sep…

Meet Iconovo at Bio-Europe Digital

October 19, 2021

Iconovo will participate at Bio-Europe Digital, an online event that will be held 25-28 October. Here we will present ICOone - our disposable single-dose…

Iconovo develops inhaled Covid-19 vaccine

October 12, 2021

BBC, and a line of other media channels, has acknowledged Iconovo and its groundbreaking work with immunotherapy company ISR for the development of inhaled…

Iconovo will participate at CPhI Milan

October 7, 2021

Iconovo will participate at the CPhI event in Milan Italy, 9-11 November 2021. Here thousands of pharma suppliers and buyers unite, connect and do business.…

ICOpre – the story behind a new, generic inhaler platform to Ellipta

October 5, 2021

Iconovo has developed a new and innovative dry powder inhaler platform - ICOpre - aimed for a global market. ICOpre is a pre-metered dry powder inhaler…

Iconovo looks to the US where it now meets quality requirements

September 27, 2021

Biostock published September 24th an article about Iconovo that can be found in its entirety below One of Iconovo’s goals is to launch future inhalation…